Vir Biotechnology
220 hedge funds and large institutions have $1.68B invested in Vir Biotechnology in 2022 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 94 increasing their positions, 54 reducing their positions, and 30 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
74% more repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 54
30% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 30
4% more funds holding
Funds holding: 211 → 220 (+9)
8% more call options, than puts
Call options by funds: $5.6M | Put options by funds: $5.17M
0.69% more ownership
Funds ownership: 64.83% → 65.52% (+0.69%)
24% less capital invested
Capital invested by funds: $2.2B → $1.68B (-$524M)
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$44M |
| 2 |
BlackRock
New York
|
+$27M |
| 3 |
Renaissance Technologies
New York
|
+$24.2M |
| 4 |
Temasek Holdings
Singapore
|
+$11M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$10.1M |
Top Sellers
| 1 |
Capital International Investors
Los Angeles,
California
|
-$61.1M |
| 2 |
APF
Alaska Permanent Fund
Juneau,
Alaska
|
-$58.6M |
| 3 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$19.9M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$19.3M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$11.9M |
VIR Hedge Fund Activity: Q3 2022 in Review
220 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q3 2022, worth a combined $1.68B — down 24% from $2.2B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new VIR positions and 30 closed out — a net gain of 9 holders — while 94 added to existing stakes and 54 trimmed.
The largest buyer was Vanguard Group, adding an estimated $44M. The largest seller was Capital International Investors, cutting an estimated $61.1M.
- 220 institutional investors held Vir Biotechnology (VIR) as of Q3 2022, up from 211 in Q2 2022.
- Funds reported $1.68B of Vir Biotechnology stock for Q3 2022, down 24% quarter-over-quarter.
- 39 funds opened new Vir Biotechnology positions in Q3 2022 and 30 closed out, a net change of +9 holders.
- The largest Vir Biotechnology buyer in Q3 2022 was Vanguard Group, an estimated $44M added.
- The largest Vir Biotechnology seller in Q3 2022 was Capital International Investors, an estimated $61.1M sold.
Based on aggregated 13F filings for Q3 2022.